Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: A potential treatment strategy

Cancer Science

Volumn 100, Issue 3, 2009, Pages 546-551

  Sato, Seiya ^a   Itamochi, Hiroaki ^a   Kigawa, Junzo ^a   Oishi, Tetsuro ^a   Shimada, Muneaki ^a   Sato, Shinya ^a   Naniwa, Jun ^a   Uegaki, Kazunori ^a   Nonaka, Michiko ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; PLATINUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; MUCINOUS CARCINOMA; NONHUMAN; NUDE MOUSE; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; COLLOID CARCINOMA; DRUG EFFECT; DRUG SCREENING; OVARY TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA, MUCINOUS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; HUMANS; MICE; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 62849118353     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01065.x     Document Type: Article

References (34)

1. McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 2002; 84: 399-403.
2. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: Incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003; 27: 985-93.
3. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008; 109: 370-6.
4. Hess V, A'Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-4.
5. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-29.
6. Winter WE 3rd, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 3621-7.
7. Pectasides D, Fountzilas G, Aravantinos G et al. Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2005; 97: 436-41.
8. Pisano C, Greggi S, Tambaro R et al. Activity of chemotherapy in mucinous epithelial ovarian cancer: A retrospective study. Anticancer Res 2005; 25: 3501-5.
9. Nakayama K, Takebayashi Y, Nakayama S et al. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett 2003; 192: 227-35.
10. Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 2006; 32: 875-86.
11. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993; 53: 5970-6.
12. Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855-65.
13. Noordhuis P, Laan AC, van de Born K, Losekoot N, Kathmann I, Peters GJ. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines. Biochem Pharmacol 2008; 76: 53-61.
14. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405-10.
15. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988; 21: 71-4.
16. Sehouli J, Stengel D, Oskay-Oezcelik G et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2008; 26: 3176-82.
17. Look KY, Blessing JA, Muss HB, DeGeest K. 5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1992; 15: 494-6.
18. Look KY, Muss HB, Blessing JA, Morris M. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 1995; 18: 19-22.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65: 55-63.
20. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
21. Park JG, Kramer BS, Steinberg SM et al. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res 1987; 47: 5875-9.
22. Gorai I, Nakazawa T, Miyagi E, Hirahara F, Nagashima Y, Minaguchi H. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. Gynecol Oncol 1995; 57: 33-46.
23. Ohta I, Gorai I, Miyamoto Y et al. Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells. Cancer Lett 2001; 162: 39-48.
24. Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol 1988; 21: 185-90.
25. Mitsuhashi Y, Inaba M, Sugiyama Y, Kobayashi T. In vitro measurement of chemosensitivity of human small cell lung and gastric cancer cell lines toward cell cycle phase-nonspecific agents under the clinically equivalent area under the curve. Cancer 1992; 70: 2540-6.
26. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998; 25: 13-22.
27. Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: A gynecologic group study. J Clin Oncol 2003; 21: 2856-9.
28. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 2006; 70: 1390-4.
29. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 2001; 48: 398-406.
30. Fink D, Nebel S, Aebi S et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-6.
31. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 2003; 39: 112-19.
32. Youn CK, Kim MH, Cho HJ et al. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res 2004; 64: 4849-57.
33. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24: 331-44.
34. Ojima E, Inoue Y, Watanabe H et al. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines. Oncol Rep 2006; 16: 1085-91.